(Q33394687)

English

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Kollmannsberger

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Hirte

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L L Siu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Mazurka

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Chi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Elit

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W Walsh

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Sederias

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Doyle

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E A Eisenhauer

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A M Oza

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

29 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

238-244

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Regulation of translation initiation by FRAP/mTOR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR063

21 January 2018

Identifiers

10.1093/ANNONC/MDR063

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394687&oldid=1568133740"